In our subsequent studies, both in vitro and in vivo experiments will be conducted to explore the specific regulatory role of dapagliflozin in the PI3K-Akt pathway and key targets against T2DM. This evidence concerns the gene PIK3CA and type 2 diabetes mellitus.